{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:22:00Z","timestamp":1793740920910,"version":"4.6.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82160530, 82360564"],"award-info":[{"award-number":["82160530, 82360564"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203493, 82372769"],"award-info":[{"award-number":["82203493, 82372769"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010857","name":"Jiangxi Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["20224ACB206037"],"award-info":[{"award-number":["20224ACB206037"]}],"id":[{"id":"10.13039\/501100010857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Gemcitabine resistance is a major clinical challenge in pancreatic cancer (PC); therefore, strategies to combat gemcitabine resistance are urgently required. Reprogramming pyrimidine metabolism by oncogenic signaling contributes to cancer progression and confers chemoresistance to many cancers. The current study identified the deubiquitinating enzyme OTUB1 as a promising therapeutic target for combating gemcitabine resistance in PC. OTUB1 was found to be aberrantly expressed in PC and remarkably correlated with poor patient survival. Both in vivo and in vitro, OTUB1 knockdown increased the gemcitabine efficacy of PC cells by inhibiting pyrimidine metabolism. Furthermore, OTUB1 enhanced de novo nucleotide pyrimidine synthesis in PC cells by upregulating dihydroorotate dehydrogenase (DHODH), a critical rate-limiting enzyme for pyrimidine de novo biosynthesis. Mechanistically, OTUB1 suppressed the degradation and polyubiquitination of the RNA-binding protein DEAD-box helicase 3 X-linked (DDX3X), which in turn stabilized DDX3X-mediated DHODH mRNA. OTUB1 interacts with DDX3X, and the binding stabilizes DDX3X through its deubiquitinase activity. In addition, a small-molecule OTUB1 inhibitor combined with gemcitabine treatment could synergistically inhibit tumor growth in high-OTUB1-expressing murine tumoroids. Collectively, OTUB1 could impart gemcitabine resistance by promoting de novo pyrimidine synthesis, and targeted suppression of OTUB1 could be an effective strategy to overcome gemcitabine resistance in PC.<\/jats:p>","DOI":"10.1038\/s41419-025-08001-4","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T14:09:32Z","timestamp":1759759772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The deubiquitylase OTUB1 drives gemcitabine resistance in pancreatic cancer by enhancing pyrimidine metabolism through modulating DHODH mRNA stability"],"prefix":"10.1038","volume":"16","author":[{"given":"Wenming","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangyan","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeqin","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8305-1900","authenticated-orcid":false,"given":"Leifeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8173-5118","authenticated-orcid":false,"given":"Xiaogang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"8001_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"8001_CR2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41575-018-0005-x","volume":"15","author":"JP Neoptolemos","year":"2018","unstructured":"Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH. Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol. 2018;15:333\u201348.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"8001_CR3","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1615\/CritRevOncog.2019031641","volume":"24","author":"D Sarvepalli","year":"2019","unstructured":"Sarvepalli D, Rashid MU, Rahman AU, Ullah W, Hussain I, Hasan B, et al. Gemcitabine: a review of chemoresistance in pancreatic cancer. Crit Rev Oncog. 2019;24:199\u2013212.","journal-title":"Crit Rev Oncog"},{"key":"8001_CR4","doi-asserted-by":"publisher","first-page":"C540","DOI":"10.1152\/ajpcell.00331.2022","volume":"324","author":"AK Beutel","year":"2023","unstructured":"Beutel AK, Halbrook CJ. Barriers and opportunities for gemcitabine in pancreatic cancer therapy. Am J Physiol Cell Physiol. 2023;324:C540\u2013c552.","journal-title":"Am J Physiol Cell Physiol"},{"key":"8001_CR5","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/bjc.2017.118","volume":"116","author":"AC Newman","year":"2017","unstructured":"Newman AC, Maddocks ODK. One-carbon metabolism in cancer. Br J Cancer. 2017;116:1499\u2013504.","journal-title":"Br J Cancer"},{"key":"8001_CR6","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1126\/science.abb4542","volume":"372","author":"K Fugger","year":"2021","unstructured":"Fugger K, Bajrami I, Silva Dos Santos M, Young SJ, Kunzelmann S, Kelly G, et al. Targeting the nucleotide salvage factor DNPH1 sensitizes BRCA-deficient cells to PARP inhibitors. Science. 2021;372:156\u201365.","journal-title":"Science"},{"key":"8001_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ccell.2017.06.004","volume":"32","author":"SK Shukla","year":"2017","unstructured":"Shukla SK, Purohit V, Mehla K, Gunda V, Chaika NV, Vernucci E, et al. MUC1 and HIF-1alpha signaling crosstalk induces anabolic glucose metabolism to impart gemcitabine resistance to pancreatic cancer. Cancer Cell. 2017;32:71\u201387.e77.","journal-title":"Cancer Cell"},{"key":"8001_CR8","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1038\/s41388-023-02643-4","volume":"42","author":"M Walter","year":"2023","unstructured":"Walter M, Mayr F, Hanna BMF, Cookson V, Mortusewicz O, Helleday T, et al. NUDT22 promotes cancer growth through pyrimidine salvage. Oncogene. 2023;42:1282\u201393.","journal-title":"Oncogene"},{"key":"8001_CR9","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1158\/0008-5472.CAN-22-2145","volume":"83","author":"S Zou","year":"2023","unstructured":"Zou S, Qin B, Yang Z, Wang W, Zhang J, Zhang Y, et al. CSN6 mediates nucleotide metabolism to promote tumor development and chemoresistance in colorectal cancer. Cancer Res. 2023;83:414\u201327.","journal-title":"Cancer Res"},{"key":"8001_CR10","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1158\/2159-8290.CD-16-0611","volume":"7","author":"KK Brown","year":"2017","unstructured":"Brown KK, Spinelli JB, Asara JM, Toker A. Adaptive reprogramming of de novo pyrimidine synthesis is a metabolic vulnerability in triple-negative breast cancer. Cancer Discov. 2017;7:391\u20139.","journal-title":"Cancer Discov"},{"key":"8001_CR11","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1158\/2159-8290.CD-16-0612","volume":"7","author":"D Mathur","year":"2017","unstructured":"Mathur D, Stratikopoulos E, Ozturk S, Steinbach N, Pegno S, Schoenfeld S, et al. PTEN regulates glutamine flux to pyrimidine synthesis and sensitivity to dihydroorotate dehydrogenase inhibition. Cancer Discov. 2017;7:380\u201390.","journal-title":"Cancer Discov"},{"key":"8001_CR12","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41568-023-00633-y","volume":"23","author":"G Dewson","year":"2023","unstructured":"Dewson G, Eichhorn PJA, Komander D. Deubiquitinases in cancer. Nat Rev Cancer. 2023;23:842\u201362.","journal-title":"Nat Rev Cancer"},{"key":"8001_CR13","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cell.2013.05.046","volume":"154","author":"TE Mevissen","year":"2013","unstructured":"Mevissen TE, Hospenthal MK, Geurink PP, Elliott PR, Akutsu M, Arnaudo N, et al. OTU deubiquitinases reveal mechanisms of linkage specificity and enable ubiquitin chain restriction analysis. Cell. 2013;154:169\u201384.","journal-title":"Cell"},{"key":"8001_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101303","volume":"67","author":"Q Zhu","year":"2021","unstructured":"Zhu Q, Fu Y, Li L, Liu CH, Zhang L. The functions and regulation of Otubains in protein homeostasis and diseases. Ageing Res Rev. 2021;67:101303.","journal-title":"Ageing Res Rev"},{"key":"8001_CR15","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1002\/hep.32179","volume":"75","author":"JL Zhang","year":"2022","unstructured":"Zhang JL, Du BB, Zhang DH, Li H, Kong LY, Fan GJ, et al. OTUB1 alleviates NASH through inhibition of the TRAF6-ASK1 signaling pathways. Hepatology. 2022;75:1218\u201334.","journal-title":"Hepatology"},{"key":"8001_CR16","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1038\/onc.2015.208","volume":"35","author":"U Karunarathna","year":"2016","unstructured":"Karunarathna U, Kongsema M, Zona S, Gong C, Cabrera E, Gomes AR, et al. OTUB1 inhibits the ubiquitination and degradation of FOXM1 in breast cancer and epirubicin resistance. Oncogene. 2016;35:1433\u201344.","journal-title":"Oncogene"},{"key":"8001_CR17","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1111\/cas.14876","volume":"112","author":"HH Zhang","year":"2021","unstructured":"Zhang HH, Li C, Ren JW, Liu L, Du XH, Gao J, et al. OTUB1 facilitates bladder cancer progression by stabilizing ATF6 in response to endoplasmic reticulum stress. Cancer Sci. 2021;112:2199\u2013209.","journal-title":"Cancer Sci"},{"key":"8001_CR18","doi-asserted-by":"publisher","first-page":"5186","DOI":"10.1038\/s41388-022-02507-3","volume":"41","author":"C Yan","year":"2022","unstructured":"Yan C, Yang H, Su P, Li X, Li Z, Wang D, et al. OTUB1 suppresses Hippo signaling via modulating YAP protein in gastric cancer. Oncogene. 2022;41:5186\u201398.","journal-title":"Oncogene"},{"key":"8001_CR19","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1038\/s41418-020-00700-z","volume":"28","author":"D Zhu","year":"2021","unstructured":"Zhu D, Xu R, Huang X, Tang Z, Tian Y, Zhang J, et al. Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1. Cell Death Differ. 2021;28:1773\u201389.","journal-title":"Cell Death Differ"},{"key":"8001_CR20","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1182\/blood.2020005199","volume":"137","author":"Y Xu","year":"2021","unstructured":"Xu Y, Xu M, Tong J, Tang X, Chen J, Chen X, et al. Targeting the Otub1\/c-Maf axis for the treatment of multiple myeloma. Blood. 2021;137:1478\u201390.","journal-title":"Blood"},{"key":"8001_CR21","doi-asserted-by":"crossref","unstructured":"Cargill M, Venkataraman R, Lee S. DEAD-box RNA helicases and genome stability. Genes. 2021;12:1471.","DOI":"10.3390\/genes12101471"},{"key":"8001_CR22","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.1093\/nar\/gkr350","volume":"39","author":"PM Wilson","year":"2011","unstructured":"Wilson PM, Labonte MJ, Russell J, Louie S, Ghobrial AA, Ladner RD. A novel fluorescence-based assay for the rapid detection and quantification of cellular deoxyribonucleoside triphosphates. Nucleic Acids Res. 2011;39:e112.","journal-title":"Nucleic Acids Res"},{"key":"8001_CR23","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.jmb.2008.12.085","volume":"386","author":"T Wang","year":"2009","unstructured":"Wang T, Yin L, Cooper EM, Lai MY, Dickey S, Pickart CM, et al. Evidence for bidentate substrate binding as the basis for the K48 linkage specificity of otubain 1. J Mol Biol. 2009;386:1011\u201323.","journal-title":"J Mol Biol"},{"key":"8001_CR24","doi-asserted-by":"publisher","first-page":"4935","DOI":"10.7150\/thno.73223","volume":"12","author":"Q Chen","year":"2022","unstructured":"Chen Q, Yang B, Liu X, Zhang XD, Zhang L, Liu T. Histone acetyltransferases CBP\/p300 in tumorigenesis and CBP\/p300 inhibitors as promising novel anticancer agents. Theranostics. 2022;12:4935\u201348.","journal-title":"Theranostics"},{"key":"8001_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.drup.2015.10.002","volume":"23","author":"Y Binenbaum","year":"2015","unstructured":"Binenbaum Y, Na\u2019ara S, Gil Z. Gemcitabine resistance in pancreatic ductal adenocarcinoma. Drug Resist Updat. 2015;23:55\u201368.","journal-title":"Drug Resist Updat"},{"key":"8001_CR26","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.canlet.2018.08.010","volume":"436","author":"T Ma","year":"2018","unstructured":"Ma T, Chen W, Zhi X, Liu H, Zhou Y, Chen BW, et al. USP9X inhibition improves gemcitabine sensitivity in pancreatic cancer by inhibiting autophagy. Cancer Lett. 2018;436:129\u201338.","journal-title":"Cancer Lett"},{"key":"8001_CR27","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2022110620","volume":"42","author":"K Shigeta","year":"2023","unstructured":"Shigeta K, Hasegawa M, Hishiki T, Naito Y, Baba Y, Mikami S, et al. IDH2 stabilizes HIF-1\u03b1-induced metabolic reprogramming and promotes chemoresistance in urothelial cancer. Embo J. 2023;42:e110620.","journal-title":"Embo J"},{"key":"8001_CR28","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1586\/14737140.3.5.717","volume":"3","author":"CM Galmarini","year":"2003","unstructured":"Galmarini CM, Jordheim L, Dumontet C. Pyrimidine nucleoside analogs in cancer treatment. Expert Rev Anticancer Ther. 2003;3:717\u201328.","journal-title":"Expert Rev Anticancer Ther"},{"key":"8001_CR29","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1053\/j.gastro.2023.02.025","volume":"164","author":"X Jiang","year":"2023","unstructured":"Jiang X, Ma Y, Wang T, Zhou H, Wang K, Shi W, et al. Targeting UBE2T potentiates gemcitabine efficacy in pancreatic cancer by regulating pyrimidine metabolism and replication stress. Gastroenterology. 2023;164:1232\u201347.","journal-title":"Gastroenterology"},{"key":"8001_CR30","doi-asserted-by":"publisher","first-page":"4341","DOI":"10.7150\/ijbs.71134","volume":"18","author":"Y Fu","year":"2022","unstructured":"Fu Y, Liu S, Rodrigues RM, Han Y, Guo C, Zhu Z, et al. Activation of VIPR1 suppresses hepatocellular carcinoma progression by regulating arginine and pyrimidine metabolism. Int J Biol Sci. 2022;18:4341\u201356.","journal-title":"Int J Biol Sci"},{"key":"8001_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04596-0","volume":"13","author":"Z Zhu","year":"2022","unstructured":"Zhu Z, Cao C, Zhang D, Zhang Z, Liu L, Wu D, et al. UBE2T-mediated Akt ubiquitination and Akt\/\u03b2-catenin activation promotes hepatocellular carcinoma development by increasing pyrimidine metabolism. Cell Death Dis. 2022;13:154.","journal-title":"Cell Death Dis"},{"key":"8001_CR32","doi-asserted-by":"publisher","first-page":"33035","DOI":"10.1074\/jbc.R400007200","volume":"279","author":"DR Evans","year":"2004","unstructured":"Evans DR, Guy HI. Mammalian pyrimidine biosynthesis: fresh insights into an ancient pathway. J Biol Chem. 2004;279:33035\u20138.","journal-title":"J Biol Chem"},{"key":"8001_CR33","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40170-021-00250-z","volume":"9","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Tao L, Zhou X, Zuo Z, Gong J, Liu X, et al. DHODH and cancer: promising prospects to be explored. Cancer Metab. 2021;9:22.","journal-title":"Cancer Metab"},{"key":"8001_CR34","doi-asserted-by":"crossref","unstructured":"Yamaguchi N, Weinberg EM, Nguyen A, Liberti MV, Goodarzi H, Janjigian YY, et al. PCK1 and DHODH drive colorectal cancer liver metastatic colonization and hypoxic growth by promoting nucleotide synthesis. Elife 2019;8:e52135.","DOI":"10.7554\/eLife.52135"},{"key":"8001_CR35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41368-020-00109-x","volume":"13","author":"X Qiu","year":"2021","unstructured":"Qiu X, Jiang S, Xiao Y, He Y, Ren T, Jiang L, et al. SOX2-dependent expression of dihydroorotate dehydrogenase regulates oral squamous cell carcinoma cell proliferation. Int J Oral Sci. 2021;13:3.","journal-title":"Int J Oral Sci"},{"key":"8001_CR36","doi-asserted-by":"publisher","first-page":"12398","DOI":"10.1074\/jbc.AC120.014189","volume":"295","author":"MC Lafita-Navarro","year":"2020","unstructured":"Lafita-Navarro MC, Perez-Castro L, Zacharias LG, Barnes S, DeBerardinis RJ, Conacci-Sorrell M. The transcription factors aryl hydrocarbon receptor and MYC cooperate in the regulation of cellular metabolism. J Biol Chem. 2020;295:12398\u2013407.","journal-title":"J Biol Chem"},{"key":"8001_CR37","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.omto.2019.04.006","volume":"14","author":"R Buettner","year":"2019","unstructured":"Buettner R, Morales C, Wu X, Sanchez JF, Li H, Melstrom LG, et al. Leflunomide synergizes with gemcitabine in growth inhibition of PC cells and impairs c-Myc signaling through PIM kinase targeting. Mol Ther Oncolytics. 2019;14:149\u201358.","journal-title":"Mol Ther Oncolytics"},{"key":"8001_CR38","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/wrna.1165","volume":"4","author":"R Soto-Rifo","year":"2013","unstructured":"Soto-Rifo R, Ohlmann T. The role of the DEAD-box RNA helicase DDX3 in mRNA metabolism. Wiley Interdiscip Rev RNA. 2013;4:369\u201385.","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"8001_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01325-7","volume":"20","author":"J Mo","year":"2021","unstructured":"Mo J, Liang H, Su C, Li P, Chen J, Zhang B. DDX3X: structure, physiologic functions and cancer. Mol Cancer. 2021;20:38.","journal-title":"Mol Cancer"},{"key":"8001_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216426","volume":"577","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Zheng L, Bai Y, Su C, Che Y, Xu J, et al. ITPR1-AS1 promotes small cell lung cancer metastasis by facilitating P21(HRAS) splicing and stabilizing DDX3X to activate the cRaf-MEK-ERK cascade. Cancer Lett. 2023;577:216426.","journal-title":"Cancer Lett"},{"key":"8001_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104994","volume":"185","author":"PT Winnard Jr.","year":"2021","unstructured":"Winnard PT Jr., Vesuna F, Raman V. Targeting host DEAD-box RNA helicase DDX3X for treating viral infections. Antiviral Res. 2021;185:104994.","journal-title":"Antiviral Res"},{"key":"8001_CR42","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1002\/1873-3468.13106","volume":"592","author":"E Cannizzaro","year":"2018","unstructured":"Cannizzaro E, Bannister AJ, Han N, Alendar A, Kouzarides T. DDX3X RNA helicase affects breast cancer cell cycle progression by regulating expression of KLF4. FEBS Lett. 2018;592:2308\u201322.","journal-title":"FEBS Lett"},{"key":"8001_CR43","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.4049\/jimmunol.1401589","volume":"194","author":"D Somma","year":"2015","unstructured":"Somma D, Mastrovito P, Grieco M, Lavorgna A, Pignalosa A, Formisano L, et al. CIKS\/DDX3X interaction controls the stability of the Zc3h12a mRNA induced by IL-17. J Immunol. 2015;194:3286\u201394.","journal-title":"J Immunol"},{"key":"8001_CR44","doi-asserted-by":"publisher","first-page":"4333","DOI":"10.7150\/thno.85421","volume":"13","author":"C Liu","year":"2023","unstructured":"Liu C, Jiang K, Ding Y, Yang A, Cai R, Bai P, et al. Kindlin-2 enhances c-Myc translation through association with DDX3X to promote pancreatic ductal adenocarcinoma progression. Theranostics. 2023;13:4333\u201355.","journal-title":"Theranostics"},{"key":"8001_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03628-9","volume":"20","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Zhou Y, Jia Y, Wang C, Zhang M, Xu Z. PRR34-AS1 promotes exosome secretion of VEGF and TGF-\u03b2 via recruiting DDX3X to stabilize Rab27a mRNA in hepatocellular carcinoma. J Transl Med. 2022;20:491.","journal-title":"J Transl Med"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08001-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08001-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08001-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T15:24:29Z","timestamp":1759764269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08001-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8001"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08001-4","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"27 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was performed in accordance with the Declaration of Helsinki. The inclusion of human participants and the use of human data and human tissue in this study were approved by the Ethics Committee of the Second Affiliated Hospital of Nanchang University. The use of animals in this study was approved by the animal research committee in the Laboratory Animal Science Center of Nanchang University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"697"}}